The global mixed mode chromatography resin market size was estimated at USD 117.5 million in 2024 and is expected to grow at a CAGR of 12.3% from 2025 to 2030. This growth is attributed to the increasing demand for biopharmaceuticals, particularly monoclonal antibodies and vaccines, necessitating efficient purification techniques to ensure high product purity and yield. In addition, the rise of single-use technologies in bioprocessing enhances operational efficiency and reduces costs.
The expansion of Contract Manufacturing Organizations (CMOs) seeking effective purification solutions further propels market growth. Moreover, ongoing advancements in chromatography resin technology improve performance and scalability, meeting the evolving needs of the industry.
The mixed-mode chromatography resin incorporates ligands with both hydrophobic and ionic characteristics, allowing it to interact with biomolecules based on their charge, hydrophobicity, and size. This capability enhances the purification processes for proteins, peptides, and nucleic acids, increasing selectivity and flexibility in separating complex mixtures. As the demand for biopharmaceuticals rises, particularly for monoclonal antibodies, vaccines, and recombinant proteins, companies seek efficient purification methods to ensure high product purity and yield.
In addition, monoclonal antibody production, crucial for therapeutic applications, particularly benefits from the effectiveness of mixed-mode chromatography resins in achieving desired purity levels and adopting single-use technologies in bioprocessing facilities, further propelling the market. These technologies integrate seamlessly with mixed-mode chromatography resins, streamlining operations while reducing costs. In monoclonal antibody production, single-use systems significantly cut setup times and eliminate the need for cleaning validations, thus enhancing overall efficiency. Furthermore, expanding Contract Manufacturing Organizations (CMOs) in the biopharmaceutical sector presents new opportunities for resin suppliers.
CMOs prioritize cost-effective purification solutions as they aim to meet increasing biopharmaceutical demand. Companies like Catalent and Lonza increasingly rely on mixed mode chromatography resins to optimize their bioprocessing operations. Moreover, advancements in chromatography resin technology are driving market growth. Innovations such as novel ligands with specific binding properties and improved resin matrices with higher binding capacities enable enhanced performance and scalability in biopharmaceutical purification processes. These developments are essential for effectively meeting the industry's evolving needs.
The ion exchange and hydrophobic interaction segment dominated the market and accounted for the largest revenue share of 50.8% in 2024 attributed to its effectiveness in separating biomolecules based on charge and hydrophobicity. This dual capability enhances protein and nucleic acid purification, making it crucial for biopharmaceutical applications. In addition, rising demand for high-purity products in drug development propels this segment forward. Furthermore, advancements in resin technology improve selectivity and binding capacities, making these techniques increasingly appealing to manufacturers seeking reliable purification solutions in modern bioprocessing.
The hydroxyapatite segment is expected to grow at a CAGR of 12.1% over the forecast period, owing to its unique ability to purify proteins based on their affinity for calcium phosphate selectively. This method is particularly useful for purifying biomolecules like antibodies and enzymes that require gentle handling to maintain their activity. In addition, the rising emphasis on biopharmaceutical research drives demand for effective purification techniques that ensure product integrity. Furthermore, advancements in hydroxyapatite resin technology improve scalability and performance, making it an appealing choice for manufacturers aiming to meet stringent quality standards in their processes.
The pharmaceutical and biotechnology segment led the market and is expected to grow at a CAGR of 12.3% from 2025 to 2030, owing to increasing investments in biopharmaceutical research and development, particularly for novel therapies like monoclonal antibodies and gene therapies, heightening the demand for effective purification techniques. In addition, chromatography plays a crucial role in ensuring the purity and efficacy of these products throughout drug manufacturing processes. Furthermore, advancements in resin technology enhance selectivity and binding capacities, making these resins indispensable for isolating complex biomolecules. Moreover, the rising prevalence of chronic diseases further propels the need for targeted therapies, driving market expansion.
The mixed mode chromatography resin market in North America dominated the global market and accounted for the largest revenue share of 35.3% in 2024 attributed to the strong presence of pharmaceutical and biotechnology companies. In addition, stringent drug purity and safety regulatory requirements necessitate advanced purification techniques, boosting demand for mixed mode chromatography resins. Furthermore, the region's well-established infrastructure and skilled workforce further enhance its capacity to support innovative chromatography solutions, solidifying North America's dominant market position.
The U.S. mixed mode chromatography resin market led the North American market and accounted for the largest revenue share in 2024, owing to robust investments in biopharmaceutical R&D and a thriving pharmaceutical sector. The demand for high-purity products drives the need for effective purification methods, particularly in biologics production. Furthermore, the presence of leading pharmaceutical companies fosters a competitive environment that encourages innovation in chromatography technologies. Regulatory pressures from agencies like the FDA also compel manufacturers to adopt advanced purification techniques, ensuring compliance with stringent quality standards and thereby driving market growth.
The mixed mode chromatography resin market in Asia Pacific is expected to grow at a CAGR of 8.3% over the forecast period. This growth is attributed to increasing investments in biopharmaceuticals and rising healthcare expenditures. Countries like China and India are expanding their pharmaceutical sectors, focusing on developing biosimilars and generics. In addition, this growth is complemented by a surge in contract manufacturing organizations (CMOs) that require efficient purification solutions. Furthermore, government initiatives to promote biotechnology research and development further stimulate demand for advanced chromatography techniques, positioning Asia Pacific as a key player in the global market.
China mixed mode chromatography resin market is expanding rapidly, driven by the country's booming biopharmaceutical industry and government support for biotechnology initiatives. In addition, the increasing focus on developing novel therapeutics and biosimilars necessitates advanced purification technologies to ensure product quality and compliance with regulatory standards. Furthermore, China's growing number of research institutions and pharmaceutical companies enhances the demand for effective separation techniques.
The mixed mode chromatography resin market in Europe held a significant revenue share in 2024 is driven by stringent regulatory requirements and a strong emphasis on drug safety and efficacy. In addition, the region's well-established pharmaceutical industry is increasingly investing in R&D for biologics and biosimilars, driving demand for advanced purification techniques. Furthermore, European countries are focusing on sustainable practices within biomanufacturing, which aligns with the capabilities of mixed-mode chromatography resins to provide efficient separation solutions. The presence of leading pharmaceutical firms and research institutions also contributes to a competitive landscape that fosters innovation in chromatography technologies.
Germany mixed mode chromatography resin market dominated the European market and is expected to grow at a CAGR of 9.4% over the forecast period, driven by its robust pharmaceutical sector and commitment to innovation. In addition, the country is home to numerous leading pharmaceutical companies that prioritize high-quality purification processes for biologics and complex molecules. Furthermore, Germany's strong focus on research and development fosters advancements in chromatography technologies, enhancing efficiency and selectivity.
Some of the key companies in the market include GE Healthcare Lifesciences, Merck KGaA, Tosoh Corp, and others. These companies adopt various strategies, including new product launches and strategic partnerships, to gain a competitive edge. Furthermore, mergers and acquisitions also enable companies to integrate innovative technologies and expand their product portfolios, driving growth in this competitive landscape.
GE Healthcare Life Sciences manufactures various chromatography products, including mixed mode resins that efficiently purify biomolecules such as proteins, peptides, and nucleic acids. The company’s offerings cater primarily to the biopharmaceutical and biotechnology segments, providing tools that enhance the productivity and quality of drug development processes. Their innovative chromatography solutions are designed to meet the evolving needs of researchers and manufacturers in the life sciences industry.
Merck KGaA produces diverse chromatography resins, including mixed-mode options that enhance the purification and separation of complex biomolecules. The company focuses on serving the pharmaceutical and biotechnology sectors, offering advanced drug development, production, and quality control solutions. Its extensive portfolio aims to support researchers in achieving high purity levels while optimizing purification workflows in biopharmaceutical manufacturing processes.
The following are the leading companies in the mixed mode chromatography resin market. These companies collectively hold the largest market share and dictate industry trends.
Report Attribute |
Details |
Market size value in 2025 |
USD 125.1 million |
Revenue forecast in 2030 |
USD 223.9 million |
Growth rate |
CAGR of 12.3% from 2025 to 2030 |
Base year for estimation |
2024 |
Historical data |
2018 - 2023 |
Forecast period |
2025 - 2030 |
Quantitative units |
Volume in Thousand Litres, Revenue in USD million, and CAGR from 2025 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Technique, end-use, region |
Regional scope |
North America, Europe, Asia Pacific |
Country scope |
U.S., Canada, Mexico, China, India, Japan, Australia, Germany, UK, Italy, Spain, France |
Key companies profiled |
GE Healthcare Lifesciences; Merck KGaA; Tosoh Corp; Purolite Corp; Danaher Corp; Bio-Rad Labs; Purolite; Sepragen Corporation; Thermo Fisher Scientific |
Customization scope |
Free report customization (equivalent to 8 analyst working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and analyzes the latest industry trends in each sub-segment from 2018 to 2030. For this study, Grand View Research has segmented the mixed mode chromatography resin market report based on technique, end-use, and region:
Technique Outlook (Volume, Thousand Litres, Revenue, USD Million, 2018 - 2030)
Ion exchange - Hydrophobic
Hydroxyapatite
Others
End-use Outlook (Volume, Thousand Litres, Revenue, USD Million, 2018 - 2030)
Pharmaceutical & Biotechnology
Regional Outlook (Volume, Thousand Litres, Revenue, USD Million, 2018 - 2030)
North America
U.S.
Europe
Germany
UK
France
Asia Pacific
India
Japan
China
South Korea
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."